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Summary  Limited  data  are  available  on  the  epidemiology,  clinical  manifestations
and  outcomes  of  patients  with  invasive  aspergillosis  in  Bahrain.  This  study  was  con-
ducted  retrospectively  to  determine  the  epidemiology  of  invasive  aspergillosis  and
its  risk  factors,  clinical  presentation,  underlying  conditions,  and  outcomes  over  the
past  ﬁve  years  in  a  major  hospital.
The  medical  records  of  patients  with  positive  Aspergillus  cultures  admitted  to  a
major  tertiary  care  hospital  in  Bahrain  during  2009—2013  were  reviewed.  Cases  were
classiﬁed  according  to  (1)  the  European  Organization  for  the  Research  and  Treatment
of  Cancer/Mycoses  Study  Group  (MSG)  criteria  (proven,  probable,  possible  IA  or  not
classiﬁable)  and  (2)  ‘‘validated’’  criteria  to  distinguish  Aspergillus  colonization  from
IA  (putative  or  proven  IA).  Demographic,  microbiologic  and  diagnostic  data  were
collected,  and  outcomes  were  recorded.A  total  of  60  patients  were  included,  of  whom  44  were  colonized  (73.3%),  and  16
had  probable  IA  (26.7%);  no  proven  or  possible  IA  cases  were  identiﬁed  according
to  the  EORTC/Mycoses  Study  Group  (MSG)  criteria.  In  comparison,  with  the  alter-
native  ‘‘validated’’  criteria,  32  were  colonized  (53.3%),  28  had  putative  IA  (46.7%),
and  none  had  proven  IA  (0%).  The  lung  was  the  most  common  site  of  infection,
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Introduction
Aspergillosis  refers  to  a  wide  variety  of  diseases  caused  by
members  of  the  genus  Aspergillus  [1].  Aspergillus  species
are  ubiquitous  organisms  commonly  found  in  soil,  water
and  decaying  vegetation  [2].  There  are  approximately
200  species  of  Aspergillus  [3].  However,  A.  fumigatus  is
the  most  frequently  encountered  species  in  human  dis-
ease,  followed  by  A.  ﬂavus, A.  terreus  and  A.  niger  [4,5].
There  are  several  types  of  aspergillosis:  the  most  com-
mon  are  allergic  aspergillosis,  aspergilloma  and  invasive
aspergillosis  [6].
Allergic  bronchopulmonary  aspergillosis  (ABPA)  is  a
hypersensitivity  reaction  to  the  fungus,  mostly  due  to
A.  fumigatus.  It  is  commonly  seen  in  patients  with  long-
standing  asthma  or  cystic  ﬁbrosis  [7].
Aspergilloma  is  the  most  common  form  of  pulmonary
involvement  by  Aspergillus  species.  The  aspergilloma
(fungal  ball)  consists  of  a  mass  of  fungal  hyphae,  inﬂam-
matory  cells,  ﬁbrin,  mucus  and  tissue  debris  and  usually
develops  in  a  pre-existing  lung  cavity  [8].
Invasive  aspergillosis  (IA)  is  a  serious  opportunistic
infection  that  commonly  affects  immunocompromised
patients,  such  as  those  with  prolonged  neutropenia
and  cancer  [9].  Patients  with  immune  suppression  as  a
result  of  solid  organ  or  bone  marrow  transplantation  and
patients  with  AIDS  are  also  at  high  risk  [10,11].
In  clinical  practice,  a  diagnosis  of  IA  is  often  suspected
when  Aspergillus  is  isolated  from  non-sterile  body  sites,
particularly  tracheal  and  bronchial  aspirates  [12].  How-
ever,  because  Aspergillus  spp.  are  ubiquitous,  one  must
be  cautious  in  attributing  a  pathogenic  role  to  fungus
isolated  from  these  samples  [13].
This  study  was  therefore  conducted  to  collect  data
from  patients  with  either  Aspergillus  colonization  or  inva-
sive  disease  in  order  to  investigate  the  epidemiology  of
invasive  aspergillosis  and  determine  the  risk  factors  for
Aspergillus  infections  along  with  the  associated  clinical
presentation,  underlying  conditions  and  outcomes.
Materials and methods
Patients and settings
The  Salmaniya  Medical  Complex  is  the  largest  public  hos-
pital  located  in  the  Salmaniya  district  of  Manama,  in
the  Kingdom  of  Bahrain.  Established  in  1979,  the  hospi-
tal  has  approximately  1200  beds.  The  hospital  receives
an  average  of  900—1000  patients  a  day  and  employs
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as  the  most  commonly  isolated  species  (53%).  Mortal-
 patients,  44%  in  probable  cases  and  32%  in  those  with
e  immunocompromised  or  had  one  or  more  predisposing
tors  for  death  among  patients  with  IA  included  older  age,
tion,  renal  replacement  therapy  and  higher  sequential
res  at  diagnosis.
ziz  University  for  Health  Sciences.  Published  by  Elsevier
ore  than  2000  physicians,  nurses  and  workers.  It  is  a
ulti-specialty  tertiary  hospital.  It  includes  specialties
n  cardiology,  dermatology,  diabetes,  endocrine  glands,
he  digestive  system,  hematology,  infectious  diseases,
nternal  diseases,  kidney  and  lung  diseases,  rheumatic
iseases  and  oncology;  it  also  provides  outpatient  ser-
ices.
In this  retrospective  study,  the  medical  records  of
ll  patients  with  a  positive  Aspergillus  culture  admit-
ed  to  the  Salmaniya  Medical  Complex,  a  major  tertiary
are  hospital  in  Bahrain,  between  January  2009  and
ecember  2013  were  reviewed.  All  consecutive  adult
>14  years)  patients  with  a  culture,  direct  examination
nd/or  histopathologic  sample  positive  for  Aspergillus
pp.  at  any  site  were  eligible  for  inclusion.  The  study  was
pproved  by  the  local  ethics  and  research  committees.
ata collection and outcomes
utpatients  were  excluded  from  the  study,  which
ncludes  only  hospitalized  patients.  Unfortunately,  it  was
ot  possible  to  report  the  number  of  outpatients  with  a
ositive  Aspergillus  culture.
Collected  patient  data  included  demographics  (i.e.,
ge,  sex,  and  nationality),  risk  factors,  underlying  dis-
ases  and  clinical  presentation,  including  signs  and
ymptoms  compatible  with  invasive  fungal  disease  (that
s,  refractory  or  recrudescent  fever,  pleuritic  chest  pain
r  rub,  dyspnea,  hemoptysis  or  worsening  lung  function).
he  organs  which  were  affected  by  Aspergillus  and  the
solated  species  were  recorded.  The  date  of  the  ﬁrst  posi-
ive  Aspergillus  culture  was  consider  the  date  of  diagnosis
f  IA.
Although  Aspergillus  species  are  well  recognized
s  common  environmental  airborne  contaminants,  the
etection  of  Aspergillus, especially  A.  fumigatus  and  A.
avus  in  sputum  cultures  from  patients  with  appropri-
te  predisposing  conditions,  is  likely  to  be  of  diagnostic
mportance,  and  empiric  antifungal  therapy  should  be
onsidered.
In  our  study,  the  microbiological  diagnosis  of
spergillosis  from  sputum  depends  on  the  Gram  stain.  To
valuate  whether  the  sample  is  acceptable,  the  presence
r  absence  of  squamous  epithelial  cells,  polymorphonu-
lear  leukocytes  and  microorganisms  was  evaluated.
ilamentous  hyphae  are  usually  seen  in  aspergillosis.  A
irect  sputum  smear  using  a  wet  preparation  of  10%
otassium  hydroxide  was  performed  in  suspected  cases
r  if  hyphae  were  seen  in  the  Gram  stain.  The  pres-
nce  of  hyaline,  branching,  septate  hyphae  consistent
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ith  Aspergillus  in  any  specimen  from  a  patient  with  sup-
orting  clinical  symptoms  was  considered  signiﬁcant.  A
emi-quantitative,  culture-based  method  involving  ordi-
ary  media  containing  blood  agar,  in  which  Aspergillus
an  grow  easily,  and  Sabouraud  dextrose  agar  was  used
n  suspected  cases  and  in  cases  in  which  the  Gram  stain
nd/or  wet  preparation  revealed  hyphae.  Aspergillus  usu-
lly  grows  rapidly;  incubation  lasted  for  7  days  at  25 ◦C
nd  37 ◦C.  Identiﬁcation  of  most  species  of  Aspergillus  in
ulture  is  generally  performed  by  examining  the  colony-
evel  and  microscopic  morphological  features  of  conidia
nd  conidiophores.
Radiologic  data  from  chest  X-rays  or  computed  tomo-
raphy  (CT)  scans  of  involved  organs  were  also  collected.
indings  suggestive  of  invasive  pulmonary  aspergillosis  on
hest  CT  scans  were  deﬁned  as  ‘‘typical’’  if  at  least  one
f  the  following  three  signs  was  present:  wedge-shaped
esion,  halo  or  air-crescent  sign,  lung  cavitation  or  nodule
14].
We  also  collected  data  on  patients  admitted  to  the
CU  and  acute  illness  severity  scores,  including  the  acute
hysiology  and  chronic  health  evaluation  (APACHE)  II
core  at  admission  [15]  and  the  sequential  organ  failure
ssessment  (SOFA)  score  [16]  on  the  day  of  the  posi-
ive  Aspergillus  culture.  Our  collected  clinical  data  also
ncluded  the  use  of  mechanical  ventilation,  vasopressor
gents  and/or  renal  replacement  therapy  (RRT)  both  at
he  time  of  the  ﬁrst  Aspergillus-positive  culture  and  dur-
ng  the  ICU  stay.
Data  regarding  antifungal  therapy  and  its  duration  as
ell  as  the  survival  rate  were  also  recorded.
In  this  study,  we  classify  patients  using  both  the  val-
dated  criteria  and  the  old  EORTC/MSG  criteria  (without
M)  when  the  validated  criteria  were  not  available  in  our
ospital,  and  we  compare  the  results.
Cases  were  classiﬁed  according  to  (1)  The
ORTC/Mycoses  Study  Group  (MSG)  criteria  (proven,
robable,  and  possible  IA  or  not  classiﬁable)  [14]
nd  (2)  ‘‘validated’’  criteria  to  distinguish  Aspergillus
olonization  from  IA  (i.e.,  putative  or  proven  IA)  [17].
tatistical analysis
escriptive  statistical  analyses.  Discrete  variables  are
eported  as  counts  (percentage)  and  continuous  variables
s  the  mean  ±  standard  deviation  or  median  (ﬁrst  to  third
nterquartile  range).
esults
linical characteristics of the data
nalysis  of  our  data  revealed  that  there  were  a  total  of
0  patients  with  a  positive  Aspergillus  culture  from  2009
hrough  2013,  of  which  40  were  Bahrainis  and  20  were
on-Bahrainis.  The  male:female  ratio  for  Bahrainis  was
6:24,  and  that  for  non-Bahrainis  was  15:5.  The  majority
f  patients  were  in  the  age  group  of  45—65  years,  with  a
ean  age  of  52.85  years.
The  clinical  characteristics  of  the  data  are  presentedn  Tables  1 and  2.  Most  patients  were  admitted  for  a  med-
cal  condition  (n  =  42,  70%),  and  most  were  admitted  for
espiratory  care  (n  =  34,  57%).  As  noted  in  Tables  1  and  2,
ll  patients  had  one  or  more  predisposing  factors  to
p
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spergillus  infection.  The  most  common  underlying  dis-
ases  were  diabetes  (n  =  14,  23%)  and  chronic  obstructive
ulmonary  disease  (COPD)  (n  =  10,  17%).  Malignancy  was
he  underlying  condition  in  nine  (15%)  patients;  one
atient  (2%)  had  undergone  solid  organ  transplants,
nd  one  patient  had  HIV.  Fourteen  (23%)  patients  were
eceiving  corticosteroid  therapy,  seven  (12%)  patients
ere  receiving  radiotherapy/chemotherapy,  and  four
7%)  were  on  immunosuppressive  therapy.  Neutropenia
as  present  in  four  patients  (7%);  however,  it  was  pro-
onged  (>10  days)  in  only  one  patient.
Of  all  cases,  19  patients  were  admitted  to  the  ICU,  and
he  most  common  reason  for  admission  was  respiratory
isease  (n  =  18,  30%).  Sepsis  and  ARDS  were  diagnosed  on
he  day  of  admission  in  11  (18%)  and  four  (7%)  patients,
espectively.
Of  the  60  total  patients,  16  had  probable  IA  (26.7%),
nd  44  were  colonized  (73.3%);  no  proven  or  possi-
le  IA  cases  were  identiﬁed  (0%)  according  to  the
ORTC/Mycoses  Study  Group  (MSG)  criteria.  In  contrast,
ccording  to  the  alternative  ‘‘validated’’  criteria,  32
atients  were  colonized  (53.3%),  and  28  had  putative  IA
46.7%);  again,  no  proven  IA  cases  were  identiﬁed  (0%)
Tables  1  and  2).
Aspergillus  fumigatus  was  the  most  commonly  iso-
ated  species  (n  =  32,  53%),  followed  by  Aspergillus  niger
n  17  cases  (28%),  Aspergillus  ﬂavus  in  seven  (12%),  and
spergillus  spp.  in  four  (7%)  specimens  (Table  3).
linical signs and radiological imaging
linical  and  radiologic  ﬁndings  are  described  in
ables  4  and  5. In  the  current  study,  60%  of  patients  pre-
ented  with  dyspnea,  33%  had  refractory  fever,  and  18%
uffered  from  worsening  lung  function.  Chest  pain  and
emoptysis  were  observed  in  5%  of  patients.  On  the  day
f  diagnosis  of  IA,  patients  with  IA  had  more  compatible
linical  signs  than  those  with  colonization.
The  radiologic  ﬁndings  were  abnormal  in  all  patients
ith  IA.  Chest  CT  was  performed  in  36  (60%)  patients,
nd  it  revealed  that  there  were  signiﬁcantly  more  radio-
ogic  ﬁndings  typical  of  IA  in  patients  with  probable  and
utative  IA  than  in  those  with  colonization.
ite of infection and diagnostic classiﬁcation
he  lung  and/or  trachea  were  the  most  common  sites  of
nfection.  Most  species  were  isolated  from  sputum/ETA.
ronchoalveolar  lavage  (BAL)  was  performed  in  12  (20%)
atients  (Table  6).
Our  data  revealed  that  COPD  was  observed  more
requently  in  patients  with  IA  than  in  patients  with  colo-
ization.  Furthermore,  patients  with  IA  were  more  likely
o  have  hematologic  malignancy  than  were  those  with
spergillus  colonization,  which  likely  explains  the  greater
roportion  of  patients  receiving  chemotherapy,  radio-
herapy  and  immunosuppressive  drugs  in  these  groups.
mong  the  patients  with  IA,  26  (40%)  stayed  in  an
mmunosuppressed  state  according  to  the  EORTC  criteria
Tables  4  and  5).
In  addition,  compared  with  colonized  patients,
atients  with  probable  and  putative  IA  also  had  higher
OFA  scores  on  the  day  of  the  ﬁrst  positive  Aspergillus
ulture  and  were  more  likely  to  have  a  diagnosis  of  sepsis
r  ARDS  at  ICU  admission.
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Table  1  EORTC/Mycosis  Study  Group  (MSG)  criteria  classiﬁcation:  clinical  characteristics  of  the  data.
All  patients  (n  =  60)  Probable  IA  (n  =  16)  Colonization  (n  =  44)
Male,  n  (%)  31  (52)  5  (31)  26  (59)
Underlying  conditions,  n  (%)
COPD  10  (17) 4  (25) 6  (14)
Chronic  heart  failure 3  (5) 0  3  (7)
Diabetes  14  (23)  6  (38)  8  (18)
Solid  tumor  3  (5)  2  (13)  1  (2)
Hematologic  cancers  6  (10)  6  (38)  0
Neutropenia  4  (7)  0  4  (9)
Radiotherapy/chemotherapy  7  (12)  7  (44)  0
Solid  organ  transplant  1  (2)  1  (6)  0
Immunosuppressive  drugs 4  (7)  3  (19)  1  (2)
HIV  1  (2)  0  1  (2)
Liver  disease  2  (3)  0  2  (5)
Chronic  hemodialysis  1  (2)  0  1  (2)
Smoking  18  (30)  6  (38)  12  (27)
Diagnostic  categories,  n  (%)
Medical  admission 42  (70) 9  (56)  33  (75)
Cardiovascular  4  (7)  0  4  (9)
Respiratory 34  (57) 9  (56)  25  (57)
Gastrointestinal  1  (2) 0  1  (2)
ID  2  (3) 0  2  (5)
Rheumatology  1  (2) 0  1  (2)
Hematology/oncology  6  (10) 5  (31) 1  (2)
Nephrology  2  (3) 1  (6) 1  (2)
Post-operative 9  (15) 1  (6) 8  (18)
Trauma 2  (3) 0  2  (5)
Others  1  (2)  0  1  (2)
ICU  admission  19  (32)  11  (69)  8  (18)
Severity  scores  and  main  diagnoses
APACHE  II  score  on  admission  15  (17—28)  11  (18—30)  4  (17—28)
Sepsis  on  ICU  admission  11  (18)  6  (38)  5  (11)
ARDS  on  ICU  admission  4  (7)  3  (19)  1  (2)
Septic  shock,  n  (%)  8  (13)  5  (31)  3  (7)
Pneumonia,  n  (%)  18  (30)  12  (75)  6  (14)
Antifungal  therapy,  n  (%)  15  (25)  6  (38)  9  (20)
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COPD, chronic obstructive pulmonary disease; IA, invasive asp
These  patients  additionally  had  a  greater  requirement
for  mechanical  ventilation,  vasopressors  or  RRT  during
their  ICU  stay.
The  length  of  ICU  stay  was  similar  in  patients  with
probable  IA,  putative  IA  and  Aspergillus  colonization
(median,  10  days  [1st—3rd  quartile,  3—27.5  days]  for  both
probable  and  putative  IA  vs.  13  days  [1st—3rd  quartile,
4—20  days]  for  colonization).
Antifungal therapy and outcomes
Antifungal  therapy  was  started  in  19  (32%)  patients.  In
41  additional  cases,  therapy  was  not  administered  on  the
basis  of  a  clinical  judgment  call.  The  median  time  from
positive  Aspergillus  culture  to  initiation  of  treatment  was
2  (0—5)  days  for  patients  with  Aspergillus  colonization,  1
(0—5)  day  for  probable  IA  and  1  (0—4)  day  for  putative
IA.
t
r
w
wnsive care unit; ARDS, acute respiratory distress syndrome;
osis.
Regarding  types  of  antifungal  therapy,  voriconazole
as  the  treatment  of  choice  for  15  patients;  the
emaining  four  patients  received  ﬂuconazole,  which  is
lso  an  antifungal  triazole  but  is  not  active  against  inva-
ive  aspergillosis,  so  we  regarded  those  patients  as  having
o  therapy.  Regarding  the  mortality  rate,  it  was  higher
mong  those  who  received  ﬂuconazole  (75%)  than  those
ho  received  voriconazole  (36%).
Mortality  was  higher  in  patients  with  probable  IA
seven  of  16,  44%)  and  putative  IA  (nine  of  28,  32%)  than
n  those  with  colonization  (eight  of  32,  25%).  Voricona-
ole  was  given  to  ﬁve  of  16  total  patients  with  probable
A  and  to  10  of  28  total  patients  with  putative  IA;  among
hose  who  received  treatment,  the  mortality  rate  was
0%  in  probable  IA  and  30%  in  putative  IA  cases.  There
ere  18  untreated  patients  with  probable  IA  and  puta-
ive  IA;  among  them,  the  mortality  rate  was  45%  and  38%,
espectively.  As  a  result,  no  changes  in  overall  survival
ere  observed  when  patients  who  received  voriconazole
ere  compared  with  untreated  patients  (Fig.  1).
Retrospective  study  of  epidemiology  and  clinical  manifestation  of  invasive  aspergillosis  53
Table  2  Alternative  ‘‘validated’’  criteria  classiﬁcation:  clinical  characteristics  of  the  data.
All  patients  (n  =  60)  Putative  IA  (n  =  58)  Colonization  (n  =  32)
Male,  n  (%)  31  (52)  14  (50)  17  (53)
Underlying  conditions,  n  (%)
COPD  10  (17)  9  (32)  1  (3)
Chronic  heart  failure  3  (5)  1  (4)  2  (6)
Diabetes  14  (23)  6  (21)  8  (25)
Solid  tumor 3  (5) 2 (7) 1 (3)
Hematologic  cancers 6  (10) 6 (21) 0
Neutropenia  4  (7) 1 (4) 3 (9)
Radiotherapy/chemotherapy  7  (12)  7  (25)  0
Solid  organ  transplant  1  (2)  1  (4)  0
Immunosuppressive  drugs  4  (7)  3  (11)  1  (3)
HIV  1  (2)  0  1  (3)
Liver  disease  2  (3)  0  2  (6)
Chronic  hemodialysis  1  (2)  0  1  (3)
Smoking  18  (30)  11  (39)  7  (22)
Diagnostic  categories,  n  (%)
Medical  admission  42  (70)  19  (68)  23  (72)
Cardiovascular  4  (7)  1  (4)  3  (9)
Respiratory  34  (57)  18  (64)  16  (50)
Gastrointestinal  1  (2)  0  1  (3)
ID  2  (3)  0  2  (6)
Rheumatology  1  (2)  0  1  (3)
Hematology/oncology  6  (10)  5  (18)  1  (3)
Nephrology  2  (3)  1  (4)  1  (3)
Post-operative 9  (15) 2 (7)  7  (22)
Trauma 2  (3)  0  2  (6)
Others  1  (2)  0  1  (3)
ICU  Admission 19  (32)  11  (39)  8  (25)
Severity  scores  and  main  diagnoses
APACHE  II  score  on  admission 15  (17—28)  11  (18—30)  4  (17—28)
Sepsis  on  ICU  admission 11  (18) 6 (21)  5  (16)
ARDS  on  ICU  admission 4  (7) 3 (11) 1 (3)
Septic  shock,  n  (%) 8  (13) 5 (18) 3 (9)
Pneumonia,  n  (%) 18  (30) 12 (43) 6 (19)
Antifungal  therapy,  n  (%)  15  (25)  10  (36)  5  (16)
APACHE, acute physiology and chronic health evaluation; ICU, inte
COPD, chronic obstructive pulmonary disease; IA, invasive aspergill
Table  3  Isolated  Aspergillus  species.
Aspergillus  species  NO  %
A.  fumigatus  32  53
A.  niger  17  28
Aspergillus  ﬂavus  7  12
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Total  60  100
Furthermore,  among  patients  with  IA,  independent
isk  factors  for  mortality  were  older  age,  higher  SOFA
cores  and  the  need  for  mechanical  ventilation  or  RRT.iscussion
spergillus  spp.  are  ubiquitous  ﬁlamentous  fungi  that  are
idespread  in  the  environment  and  are  responsible  for  a
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road  spectrum  of  illnesses,  from  saprophytic  coloniza-
ion  to  rapidly  disseminated  and  invasive  disease.
The  true  epidemiology  of  IA  remains  uncertain  and
ay  be  inﬂuenced  by  many  environmental  factors  and
iagnostic  strategies.
In  our  retrospective  study  of  60  patients  with
spergillus-positive  cultures,  26.7%  were  diagnosed  with
robable  IA  and  46.7%  were  diagnosed  with  puta-
ive  IA  according  to  the  EORTC/Mycoses  Study  Group
MSG)  criteria  [14]  and  the  alternative  ‘‘validated’’
riteria  [17].  Compared  with  patients  with  Aspergillus
olonization,  more  patients  with  IA  had  COPD,  hema-
ologic  malignancies  and/or  were  receiving  radiother-
py/chemotherapy;  additionally,  most  patients  were  on
mmunosuppressive  drug  or  corticosteroid  therapy.  In
eviewing  the  surveillance  of  IA  in  Europe,  the  USA  and
apan,  we  found  that  over  10  million  patients  are  at
igh  risk  of  invasive  aspergillosis  (IA)  each  year  because
f  corticosteroid  treatments  or  other  immunosuppress-
ve  therapies.  Among  those  cases,  more  than  200,000
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Table  4  EORTC/Mycosis  Study  Group  (MSG)  criteria  classiﬁcation:  clinical,  radiologic  and  microbiologic  ﬁndings
correlated  to  Aspergillus  diagnosis.
All  patients  (n  =  60)  Probable  IA  (n  = 16)  Colonization  (n  =  44)
SOFA  II  score  at  diagnosis  26  (4—14)  11  (9—14)  15  (4—10)
EORTC  host  factors,  n  (%)
Neutropenia  4  (7)  1  (6)  3  (7)
Allogeneic  stem  cell  transplant 1  (2)  1  (6)  0
Prolonged  use  of  corticosteroids 1  1  (6) 0
T-cell  immunosuppressant 11  11  (67) 0
Inherited  severe  immunodeﬁciency 3  2  (13) 1  (2)
Abnormal  radiologic  ﬁndings
Chest  X-ray/CT  scan,  n  (%)  48  (80)  16  (100)  32  (73)
Non-speciﬁc  chest  CT  scan  32  (53)  0  32  (73)
‘‘Typical’’  chest  CT  scan  ﬁndings,  n  16  (27)  16  (100)  0
Mycological  criteria
Direct  test  60  16  (100)  44  (100)
Indirect  test  NA  NA  NA
Microbiologic  ﬁndings
BALa/ETA/Sputum,  n  60  16  44
Sputum,  n  (%)  30  (50)  10  (63)  20  (45)
ETA,  n  (%) 18  (30)  4  (25)  14  (32)
BALa performed,  n  (%) 12  (20)  2  (13)  10  (23)
Isolated  species,  n  (%)
Aspergillus  fumigatus 32  (53)  6  (38)  26  (59)
Aspergillus  ﬂavus 7  (12) 3  (19)  4  (9)
Aspergillus  niger 17  (28) 3  (19) 14  (32)
Others  4  (7) 4  (25) 0
Organ  support  at  time  of  diagnosis,  n  (%)
Vasopressor  therapy 8  (13) 5  (31)  3  (7)
RRT 3  (5) 1  (6) 2  (5)
Mechanical  ventilation 11  (18) 5  (31) 3  (7)
a BAL, bronchoalveolar lavage; CT, computed tomography; EORTC, European Organization for Research and Treatment of Cancer;
NA, not available; ETA, endotracheal aspirate; IA, invasive aspergillosis; RRT, renal replacement therapy; SOFA, Sepsis Organ Failure
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patients  develop  IA  annually;  the  key  groups  that  develop
IA  include  acute  leukemia  patients,  among  whom  approx-
imately  10%  develop  IA  (300,000  new  acute  leukemia
cases  and  30,000  IA  cases,  annually)  and  patients  receiv-
ing  stem  cell  and  other  transplants  (>75,000  cases
annually  in  the  USA,  Europe  and  Japan,  approximately
10%  develop  IA,  leading  to  7500  IA  cases).  Additionally,
1.3%  of  COPD  patients  admitted  to  the  hospital  develop
IA  (7%  of  the  global  total  of  65M  moderate  and  severe
COPD  cases  (WHO),  leading  to  60,000  conﬁrmed  IA  cases)
[18—20].
In  patients  with  COPD,  the  frequency  of  Aspergillus
isolates  from  lower  respiratory  tract  samples  has  pro-
gressively  increased  [21].  In  our  study,  10  (17%)  positive
Aspergillus  cultures  were  isolated  from  COPD  patients;
four  patients  were  diagnosed  with  probable  IA,  and  nine
patients  were  diagnosed  with  putative  IA.  The  patients
with  IA  frequently  presented  with  severe  disease,  were
recurrently  admitted  to  the  hospital  with  exacerbation
of  symptoms  and  had  been  receiving  prolonged  courses
of  corticosteroid  therapy.In  one  study,  of  118  patients  with  COPD,  40%  had  IA
and  60%  were  colonized  [22].  The  patients  with  IA  in  that
study  were  categorized  as  having  advanced  respiratory
disease  according  to  the  Global  Initiative  for  Obstructive
a
p
p
pung  Disease  classiﬁcation.  The  study  showed  that  the
atients  with  IA  had  higher  severity  scores  and  worse
rognoses  than  the  patients  with  Aspergillus  coloniza-
ion.  The  emergence  and  occurrence  of  IA  in  patients  with
OPD  is  mainly  attributed  to  prolonged  administration
f  corticosteroid  therapy  [23].  It  appears  that  cortico-
teroids  predispose  patients  to  opportunistic  infections
hrough  quantitative  and  qualitative  functional  impair-
ent  of  neutrophil  and  macrophage  function  [23].
Invasive  aspergillosis  is  a  life-threatening  complica-
ion  as  well  in  immunocompromised  patients,  particularly
n  those  undergoing  bone  marrow  transplantation,  receiv-
ng  chemotherapy  for  hematological  malignancy  and/or
n  immunosuppressive  drugs  [24].  Prolonged  neutropenia
nd  solid  organ  transplant  have  also  been  recognized  as
trong  risk  factors  for  IA  [25—28].
In  our  study,  six  patients  with  IA  had  a  hema-
ologic  malignancy  and  were  receiving  chemotherapy.
he  estimated  mortality  among  those  patients  was
7%.  In  the  present  study,  we  reported  on  only  one
atient  who  had  undergone  renal  transplantation,  had positive  Aspergillus  culture  and  was  diagnosed  with
robable/putative  IA.  Neutropenia  was  noted  in  four
atients  with  a  positive  Aspergillus  culture,  but  it  was
rolonged  in  only  one  patient  who  was  diagnosed  with
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Table  5  Alternative  ‘‘validated’’  criteria  classiﬁcation:  clinical,  radiologic  and  microbiologic  ﬁndings  correlated
to  Aspergillus  diagnosis.
All  patients  (n  = 60)  Putative  IA  (n  =  28)  Colonization  (n  =  32)
SOFA  II  score  at  diagnosis  26  (4—14)  14  (9—14)  12  (4—10)
Clinical  signs,  n  (%)
At  least  one  of  the  following  signs
Refractory  fever 20  (33)  13  (46)  7  (22)
Pleuritic  chest  pain 5  (8) 3  (11) 2  (6)
Pleuritic  rub 2  (3) 2  (7) 0
Dyspnea  36  (60) 25  (89) 11  (34)
Hemoptysis  5  (8)  4  (14)  1  (3)
Worsening  lung  function  11  (18)  5  (18)  6  (19)
Abnormal  radiologic  ﬁndings
Chest  X-ray/CT  scan,  n  (%)  48  (80)  26  (93)  22  (69)
Non-speciﬁc  chest  CT  scan  32  (53)  12  (43)  20  (63)
‘‘Typical’’  chest  CT  scan  ﬁndings,  n  16  (27)  16  (57)  0
Microbiologic  ﬁndings
BALa/ETA/Sputum,  n  60  28  32
Sputum,  n  (%)  30  (50)  16  (57)  14  (44)
ETA,  n  (%)  18  (30)  6  (21)  12  (37)
BALa performed,  n  (%) 12 (20)  6  (21)  6  (19)
Isolated  species,  n  (%)
Aspergillus  fumigatus 32  (53) 14  (50)  18  (56)
Aspergillus  ﬂavus 7 (12)  4  (14)  3  (9)
Aspergillus  niger 17  (28) 6  (22)  11  (35)
Others  4  (7) 4  (14) 0
EORTC  host  factors,  n  (%)
EORTC  host  factor  present  on  diagnosis 26  (43) 21  (75) 5  (16)
Neutropenia  4  (7) 1  (4)  3  (9)
Malignancy  under  cytotoxic  therapy 7  (12) 7  (25) 0
Glucocorticoid  treatment 14  (23) 12  (43) 2  (6)
Inherited  severe  immunodeﬁciency  1  (2)  1  (4)  0
Organ  support  at  time  of  diagnosis,  n  (%)
Vasopressor  therapy  8  (13)  5  (18)  3  (9)
RRT  3  (5)  2  (7)  1  (3)
Mechanical  ventilation  11  (18)  5  (18)  3  (9)
a BAL, bronchoalveolar lavage; CT, computed tomography; EORTC
ETA, endotracheal aspirate; IA, invasive aspergillosis; RRT, renal re
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placement therapy; SOFA, Sepsis Organ Failure Assessment.
robable/putative  IA.  Fungal  infections  continue  to  be  a
ajor  problem  for  these  patients  [10].  As  described  by
erson  et  al.  [29],  the  key  risk  factor  of  IPA  occurrence
as  the  intensity  and  duration  of  neutropenia.
Another  signiﬁcant  risk  factor  in  this  study  was  dia-
etes  mellitus,  which  occurred  in  six  patients  with  IA;
ve  of  them  had  more  than  one  risk  factor.  Diabetes
s  a  common  metabolic  disorder  with  signiﬁcant  mor-
idity  and  mortality.  Diabetes  is  commonly  considered
s  a  risk  factor  of  mycosis  [10,30,31]. The  most  com-
on  fungal  infections  are  isolated  from  the  respiratory
ract,  skin  and  urinary  tract  [30].  However,  the  rea-
on  for  high  susceptibility  in  diabetic  patients  remains
nclear.
Fever  is  a  common  presentation  in  neutropenic
atients  and  should  not  be  considered  an  index  of
spergillosis  [32].  However,  in  our  study,  46%  of  patients
ho  developed  invasive  pulmonary  aspergillosis  (IPA)  had
efractory  fever  in  the  days  before  IPA  diagnosis.  The
ther  distinguishing  clinical  signs  of  IPA  are  chest  pain
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Table  6  Specimens  with  positive  Aspergillus  culture.
Sample  NO  %
Sputum  30  50
ETAa 18  30
BALb 12  20
Total  60  100
a ETA, endotracheal aspirate.
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and  hemoptysis  [33].  We  observed  these  signs  with  a  fre-
quency  of  11%  and  14%,  respectively.
In  our  study,  the  radiologic  manifestations  were  non-
speciﬁc  and  may  have  been  masked  by  an  underlying
acute  process.  Our  study  found  only  16  patients  with
probable/putative  IA  who  had  a  halo  sign  or  cavitation
visualized  on  chest  CT  scans.  Although  Barberan  et  al.
revealed  that  radiologic  worsening  or  cavitation  visual-
ized  on  chest  X-rays  and/or  CT  scans  was  associated  with
IA  [34],  in  another  study,  up  to  60%  of  cases  of  IA  were
exclusively  diagnosed  by  autopsy  because  of  the  absence
of  reliable  clinical  and  radiologic  signs  [35].  The  use  of
a  clinical  algorithm  to  discriminate  colonization  from  IA
[17]  remains  a  valid  option  for  recognizing  patients  who
require  a  more  extensive  diagnostic  workup.
Compared  with  patients  with  Aspergillus  colonization,
patients  with  probable/putative  IA  are  more  critically  ill
and  require  ICU  care.  Patients  with  IA  had  a  higher  inci-
dence  of  medically  necessary  ICU  admissions  and  higher
SOFA  scores  than  patients  with  colonization.  Further-
more,  patients  with  IA  more  frequently  presented  with
sepsis  and/or  ARDS  upon  admission,  needed  supportive
therapy,  mechanical  ventilation  or  RRT  and  were  associ-
ated  with  poor  outcomes.
In  the  present  study,  11  patients  with  proba-
ble/putative  IA  were  admitted  to  the  ICU  with  high
APACHE  II  scores  on  admission.  Six  patients  were  diag-
nosed  with  sepsis  and  three  patients  with  ARDS  upon  ICU
admission.  Five  patients  developed  septic  shock,  and  5
patients  required  mechanical  ventilation.  Five  patients
received  vasopressor  therapy  and  2  needed  RRT.
Limited  studies  have  been  carried  out  on  the  epidemi-
ology  of  IA  in  ICUs.  In  a  large  US  cohort,  ICU  patients
with  aspergillosis  were  found  to  have  several  comor-
bidities,  prolonged  hospitalization,  high  mortality  rates
and  increased  costs  [36].  More  speciﬁcally,  over  70%  of
patients  required  ventilation  and  received  high-dose  cor-
ticosteroids,  and  more  than  35%  had  acute  renal  failure,
COPD  or  septic  shock.
In  a  multicenter  Italian  study,  aspergillosis  repre-
sented  35  of  384  invasive  mycoses  in  ICU  patients  [37].
Antifungal  therapy  was  started  in  19  (32%)  patients.  No
signiﬁcant  differences  in  the  median  time  from  positive
Aspergillus  culture  to  the  initiation  of  treatment  were
reported  between  the  groups  (i.e.,  2  days  for  patients
with  Aspergillus  colonization,  1  day  for  patients  with
probable  IA  and  1  day  for  patients  with  putative  IA).
Mortality  was  higher  in  patients  with  probable  IA  (7  of
16,  44%)  and  putative  IA  (9  of  28,  32%)  than  in  those  with
colonization  (8  of  32,  25%).  Among  patients  with  IA,  no
changes  in  overall  survival  were  observed  when  patients
who  received  antifungal  treatment  were  compared  with
untreated  patients  (Fig.  1).
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In  our  study,  voriconazole  was  the  treatment  of  choice
or  15  of  19  total  patients  who  received  antifungal  ther-
py.  The  mortality  rate  was  higher  in  those  who  received
ther  types  of  antifungal  therapy  (75%)  than  those  who
eceived  voriconazole  (36%).
Studies  show  that  voriconazole  has  become  the  new
tandard  of  care  in  the  treatment  of  patients  with
nvasive  aspergillosis,  which  may  occur  in  immuno-
ompromised  patients,  including  patients  experiencing
ematologic  cancers,  allogeneic  BMT  and  solid  organ
ransplants.  This  has  been  established  based  on  the
esults  of  a  large,  randomized  study  in  which  voriconazole
roved  superior  to  amphotericin  B;  53%  of  subjects  had
omplete  or  partial  response  to  voriconazole,  whereas
nly  32%  had  a  similar  response  to  amphotericin  B  [38].
Other  independent  risk  factors  were  associated  with
ortality  in  patients  with  IA,  including  older  age,  higher
OFA  scores  and  the  need  for  mechanical  ventilation  or
RT.
Our  study  has  some  limitations.  First,  we  could  not
se  a speciﬁc  multimodal  diagnostic  approach  for  our
nalysis  because  not  all  patients  underwent  CT  scans.
urthermore,  GM  measurements  are  not  available  in
ur  hospital.  Additionally,  we  included  only  patients
ith  Aspergillus-positive  cultures,  thereby  eliminating
atients  with  suspected  disease  based  on  radiologic  imag-
ng  or  biomarkers.
Second,  we  did  not  assess  causes  of  death  and  cannot
xclude  the  possibility  that  some  patients  died  because
f  concomitant  illnesses.
Third,  we  did  not  gather  data  on  daily  corticosteroid
oses  and  could  not  fully  assess  the  inﬂuence  of  dose  or
uration  on  mortality.
Fourth,  autopsy  would  likely  have  increased  the  num-
er  of  cases  of  IA  diagnosis.  Autopsy  studies  have  shown
hat  IA  is  the  most  commonly  missed  infectious  diagnosis
n  patients  needing  ICU  admission  [39—41].
onclusion
his  study  implies  that  clinicians  should  be  aware  of
he  potential  fungal  etiology  of  cases  of  refractory  fever
hat  are  unresponsive  to  conventional  medical  ther-
py.  Therefore,  immediate  testing,  including  sampling  of
espiratory  ﬂuids,  biopsy  specimens  and  other  specimens
hat  can  be  processed  for  fungal  culture,  must  be  part  of
 patient’s  diagnostic  workup.  There  is  a clear  delay  in
he  diagnosis  and  treatment  of  these  cases.
Invasive  aspergillosis  is  a  life-threatening  disease,  so
n  aggressive  approach  for  high  risk  patients  is  neces-
ary;  the  approach  should  aim  to  recognize  patients  as
oon  as  possible  and  initiate  antifungal  therapy  promptly.
dditionally,  early  treatment  may  improve  the  prognosis
nd  outcome.  However,  this  aim  remains  challenging  to
chieve.  When  diagnosis  is  conﬁrmed,  it  is  often  already
oo  late.
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